article thumbnail

Top 10 Drug Discovery Trends at the Top 20 Pharma

PerkinElmer

Biochemical assays have the highest success rate. Dr. Eckelt conducted 23 hour-long, 1:1 interviews over five months in 2020 to gather market insights on how the top 20 Pharma are increasing productivity, efficiency, and speed of drug discovery in the short and long-term. Biologics are booming. Think again.

article thumbnail

Unique self-activating proteins for drug discovery

Drug Target Review

Å resolution) 6 is now being targeted for small molecule inhibitor discovery and development, by exploiting emergent computational tools to identify potential candidate compounds in silico and then test these predicted inhibitors in in vitro biochemical assays.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Are fused tetrahydroquinolines interfering with your assay?

Molecular Design

Now let’s suppose that each of a large number of targets is hit by at least one of the compounds in this selection (I could easily satisfy this requirement by selecting marketed drugs with benzene rings in their molecular structures).

article thumbnail

Analysis Life Sciences Thank You Amid broader shift on LDT policy, FDA unveils pilot program for cancer drug-linked tests and diagnostics

Agency IQ

Further, footnote 7 in the document explains: “Examples of such clinical laboratory tests are commonly used and well understood biochemical assays (e.g., This means that there are drugs for which the FDA has determined do require the use of a CDx for which there is no “contemporaneous marketing authorization of a corresponding” CDx.

FDA 40
article thumbnail

Article FDA Thank You Draft guidance on potency assays for CGT products garners extensive stakeholder input

Agency IQ

Assays are tests designed to assess various properties (like potency) of chemical or biological samples. In particular, potency has played a central role in some of the agency’s recent decisions to issue clinical holds or deny marketing approval. Should potency assurance plans be submitted? If so, how?